Clinical trials: Overweight and Obesity
Obesity, Overweight
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
The purpose of this Master Protocol is to support two studies to see how well and how safely orforglipron works compared to placebo in participants who have obesity or overweight with or without type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- NCT06993792
- Testing
- Orforglipron
- Where
- 80 sites in United States, Argentina and 5 more
- Volunteers
- 1,400 people
- Sponsor
- Eli Lilly and Company
Obesity
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide.
- Trial name
- NCT06131437
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 46 sites in United States
- Volunteers
- 809 people
- Sponsor
- Novo Nordisk A/S
Obesity & Overweight
Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults
This is a phase 2 randomized, double-blind, placebo-controlled, multi-center study evaluating the efficacy and safety of LUM-201 plus Semaglutide versus Semaglutide plus placebo in obese adults with body mass index between 30 and…
- Trial name
- NCT07754045
- Testing
- LUM-201, Semagludtide
- Volunteers
- 202 people
- Sponsor
- Lumos Pharma
Obesity
Safety and Efficacy of Low Doses of V24343 in Obese Subjects
Randomised, double-blind, parallel group comparison of four dose levels of V24343 and placebo to study the effect of V24343 on blood pressure and weight in obese subjects.
- Trial name
- NCT00734201
- Testing
- V24343
- Where
- United Kingdom
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Vernalis (R&D) Ltd
Overweight and/or Obesity
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.
- Trial name
- NCT07673900
- Testing
- VX-201, semaglutide SC
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Terrestrial Bio, Inc.
Healthy
A Study To Compare The Pharmacokinetics Of Different Formulations Of PF-04937319 In Healthy Subjects
This study is designed to compare the pharmacokinetics of three different formulations of Pf-04937319
- Trial name
- NCT01513928
- Testing
- Pf-04937319
- Where
- Singapore
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity
A Study on Efficacy and Safety of Topiramate in Maintaining Weight Loss in Obese Patients Following an Intensive, Non-Pharmacologic Weight Loss Program
The purpose of this study is to compare the efficacy and safety of topiramate 96mg and 192mg daily) with placebo in the treatment of obesity following an intensive non-pharmacologic weight loss program.
- Trial name
- NCT00236600
- Testing
- topiramate
- Volunteers
- 561 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Obesity, Diabetes Mellitus, Type 2
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study.
- Trial name
- NCT05649137
- Testing
- Semaglutide
- Where
- 76 sites in United States, Bulgaria and 6 more
- Volunteers
- 512 people
- Sponsor
- Novo Nordisk A/S
Obesity
Efficacy, Safety, and Pharmacokinetics of Tirzepatide (LY3298176) Once Weekly Versus Placebo in Pediatric Participants 6 to Less Than 12 Years of Age Who Have Obesity (ADVANCE-SURMOUNT-KIDS)
The main purpose of this study, performed under Master Protocol J4M-MC-PWMP (NCT06672549), is to evaluate the efficacy, safety, and pharmacokinetics of tirzepatide as an addition to healthy lifestyle in participants 6 to less…
- Trial name
- NCT07817875
- Testing
- Tirzepatide
- Where
- 82 sites in United States, Belgium and 8 more
- Volunteers
- 150 people
- Sponsor
- Eli Lilly and Company
Childhood Obesity
Leveraging Interactive Digital Technology to Increase Access to Family-Based Behavioral Treatment for Childhood Obesity
The primary goal of this SBIR Direct to Phase II is to expand upon the existing training platform to create an "all-in-one" digital product, FBT 2.0, that offers an integrated suite of intervention components, including (a)…
- Trial name
- FBT 2 (NCT06728800)
- Testing
- FBT 2.0, Delayed-Start Control (AAP educational materials)
- Where
- United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- 3-C Institute for Social Development
Obesity, Nutritional and Metabolic Diseases
A Study of the Safety and Effectiveness of JNJ-16269110 (R256918) in Overweight and Obese Patients
This study investigates the effectiveness and safety of 12 weeks of treatment with JNJ-16269110 (R256918), in overweight and obese patients.
- Conditions
- Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT00622765
- Testing
- R256918
- Where
- 18 sites in Belgium, Denmark and 5 more
- Volunteers
- 321 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Overweight , Obesity
TRPTI Metabolic and GLP-1 Pharmacodynamic Study
The goal of this clinical trial is to assess whether TRPTI™ supplementation affects GLP-1 and related metabolic markers in generally healthy adults who are overweight or obese (BMI 25.0-34.9 kg/m², aged 30 years and older).
- Trial name
- NCT07850466
- Testing
- TRPTI
- Where
- Australia
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- RDC Clinical Pty Ltd
Obesity, Overweight
A Study to Evaluate the Drug Interactions of HRS-7535 With Acetaminophen, Digoxin, Rosuvastatin, and Omeprazole in Obese or Overweight Subjects
This study is an open-label, fixed-sequence, self-controlled Phase I clinical trial conducted among obese or overweight subjects, with a planned enrollment of 40 adult subjects.
- Trial name
- NCT07269756
- Testing
- HRS-7535 Tablets, Paracetamol Tablets, Digoxin Tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Obese Children and Adolescents
Digital Wellness Nurse - FIT Families: Virtual Family Intervention for Adolescent Obesity
The purpose of the research is to evaluate the digital wellness nurse (DWN) app to find out if it is helpful in delivering the FIT Families intervention. The study is sponsored by the National Institutes of Health (NIH).
- Trial name
- DWN-FIT (NCT07087808)
- Testing
- Digital Wellness Nurse - FIT Families
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Machine and Human Interaction
Obesity, Overweight
A Study of Brenipatide (LY3537031) in Healthy Participants With Overweight or Obesity
The main purpose of this study is to evaluate how different dose levels of brenipatide work and how safe they are in healthy people with overweight or obesity.
- Trial name
- NCT07476118
- Testing
- Brenipatide
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Obesity
Vagal Blocking for Obesity Control
To determine the safety, efficacy and treatment algorithm(s) of the Maestro System in causing weight loss in obese subjects - This study will provide feasibility data regarding the potential of intra-abdominal vagus nerve…
- Trial name
- NCT00555958
- Testing
- Active, implantable, intra-abdominal vagal blocking medical device
- Where
- 5 sites in Australia, Mexico and 2 more
- Volunteers
- 120 people
- Sponsor
- ReShape Lifesciences
Otherwise Healthy Overweight or Obese
A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Doses of PHP-303 in Otherwise Healthy Overweight or Obese Subjects
This is a Phase 1, randomized, double-blind, placebo-controlled multiple-ascending dose (MAD) study designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of PHP-303 in otherwise healthy overweight or obese…
- Trial name
- NCT03775278
- Testing
- PHP-303
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- pH Pharma
Obesity & Overweight
UBT251 Injection Phase Ⅲ Study (Overweight or Obesity)
This randomized, double-blind, parallel, placebo-controlled phase Ⅲ study to evaluate the efficacy and safety of UBT251 Injection in overweight/obese patients
- Trial name
- NCT07648225
- Testing
- UBT251 Injection 4.0 mg, UBT251 Injection 6.0 mg
- Where
- China
- Volunteers
- 600 people
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
Morbid Obesity
Pilot Study of the Endolumik Gastric Calibration Tube for Bariatric Surgery
The pilot study will be a First In Human Clinical Trial to evaluate the Endolumik Gastric Calibration Tube and associated methods in a human clinical cohort of 20-30 bariatric patients at two high-volume bariatric programs.
- Trial name
- NCT05486325
- Testing
- Endolumik Gastric Calibration Tube (EGCT)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Endolumik, Inc
Overweight, Obese
AZD7687 Multiple Ascending Dose Study
The aim of the study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD7687 following multiple ascending dose administrations in in overweight to obese but otherwise healthy male subjects
- Trial name
- NCT01119352
- Testing
- AZD7687
- Where
- United Kingdom
- Volunteers
- 45 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.